Literature DB >> 23838220

Ventilator-associated tracheobronchitis increases the length of intensive care unit stay.

Marios Karvouniaris1, Demosthenes Makris, Efstratios Manoulakas, Paris Zygoulis, Konstantinos Mantzarlis, Apostolos Triantaris, Maria Chatzi, Epaminondas Zakynthinos.   

Abstract

OBJECTIVE: To investigate prospectively the clinical course and risk factors for ventilator-associated tracheobronchitis (VAT) and the impact of VAT on intensive care unit (ICU) morbidity and mortality.
DESIGN: Prospective cohort study.
SETTING: University Hospital Larissa, Larissa, Greece. PATIENTS: Critical care patients who received mechanical ventilation for more than 48 hours were prospectively studied between 2009 and 2011.
METHODS: The modified Clinical Pulmonary Infection Score, white blood cell count, and C-reactive protein level were systematically assessed every 2 days for the first 2 weeks of ICU stay. Bronchial secretions were assessed daily. Quantitative cultures of endotracheal secretions were performed on the first ICU day for every patient and every 2 days thereafter for the first 2 weeks or more at the discretion of the attending physicians. Definition of VAT was based on previously published criteria.
RESULTS: A total of 236 patients were observed; 42 patients (18%) presented with VAT. Gram-negative pathogens, which were usually multidrug resistant, were responsible for 92.9% of cases. Patients with a neurosurgical admission presented with VAT significantly more often than did other ICU patients (28.5% vs 14.1%; . The occurrence P=.02) of VAT was a significant risk factor for increased duration of ICU stay (OR [95% CI], 3.04 [1.35–6.85]; P=.01). Age (OR [95% CI], 1.04 [1.015–1.06]; P=.02), Acute Physiology and Chronic Health Evaluation II score (OR [95% CI], 1.08 [1.015–1.16]; P=.02), and C-reactive protein level at admission (OR [95% CI], 1.05 [1.01–1.1]; P=.02) were independent factors for ICU mortality.
CONCLUSIONS: VAT is a nosocomial infection that might be associated with prolonged stay in the ICU, especially in neurocritical patients. VAT was not associated with increased mortality in our study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838220     DOI: 10.1086/671274

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Frequency, Etiology, Mortality, Cost, and Prevention of Respiratory Tract Infections-Prospective, One Center Study.

Authors:  Wieslawa Duszynska; Marta Idziak; Klaudia Smardz; Anna Burkot; Malgorzata Grotowska; Stanislaw Rojek
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

2.  Ventilator-associated tracheobronchitis: where are we now?

Authors:  Saad Nseir; Ignacio Martin-Loeches
Journal:  Rev Bras Ter Intensiva       Date:  2014 Jul-Sep

3.  Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis.

Authors:  Kimberly C Claeys; Evan J Zasowski; Trang D Trinh; Abdalhamid M Lagnf; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2017-11-21

4.  A prospective study of ventilator-associated tracheobronchitis: Incidence and etiology in intensive care unit of a tertiary care hospital.

Authors:  Ujjwayini Ray; Suresh Ramasubban; Chandrashish Chakravarty; Lawni Goswami; Soma Dutta
Journal:  Lung India       Date:  2017 May-Jun

5.  Risk factors for mortality in ventilator-associated tracheobronchitis: a case-control study.

Authors:  Leonilda Giani Pontes; Fernando Gatti de Menezes; Priscila Gonçalves; Alexandra do Rosário Toniolo; Claudia Vallone Silva; Julia Yaeko Kawagoe; Camila Marques Dos Santos; Helena Maria Fernandes Castagna; Marinês Dalla Valle Martino; Luci Corrêa
Journal:  Einstein (Sao Paulo)       Date:  2017

Review 6.  Host-pathogen interaction during mechanical ventilation: systemic or compartmentalized response?

Authors:  Sean Keane; Ignacio Martin-Loeches
Journal:  Crit Care       Date:  2019-06-14       Impact factor: 9.097

Review 7.  Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?

Authors:  Despoina Koulenti; Kostoula Arvaniti; Mathew Judd; Natasha Lalos; Iona Tjoeng; Elena Xu; Apostolos Armaganidis; Jeffrey Lipman
Journal:  Antibiotics (Basel)       Date:  2020-01-31

Review 8.  Antibiotic therapy in ventilator-associated tracheobronchitis: a literature review.

Authors:  Abel Eduardo Alves; José Manuel Pereira
Journal:  Rev Bras Ter Intensiva       Date:  2018-03

9.  Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections.

Authors:  Anahita Rouzé; Pauline Boddaert; Ignacio Martin-Loeches; Pedro Povoa; Alejandro Rodriguez; Nassima Ramdane; Jorge Salluh; Marion Houard; Saad Nseir
Journal:  Microorganisms       Date:  2020-01-23

10.  Ventilator-associated tracheobronchitis: an update.

Authors:  Jorge Ibrain Figueira Salluh; Vicente Cés de Souza-Dantas; Ignacio Martin-Loeches; Thiago Costa Lisboa; Ligia Sarmet Cunha Farah Rabello; Nseir Saad; Pedro Póvoa
Journal:  Rev Bras Ter Intensiva       Date:  2019 Oct-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.